Share on StockTwits
 

United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine A. Rothblatt unloaded 3,833 shares of United Therapeutics Corp. stock on the open market in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $111.21, for a total value of $426,267.93. Following the completion of the sale, the chief executive officer now directly owns 140 shares of the company’s stock, valued at approximately $15,569. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded up 2.56% on Thursday, hitting $113.32. The stock had a trading volume of 869,134 shares. United Therapeutics Corp. has a 1-year low of $51.82 and a 1-year high of $116.65. The stock has a 50-day moving average of $101.0 and a 200-day moving average of $83.92. The company has a market cap of $5.692 billion and a price-to-earnings ratio of 20.08.

United Therapeutics Corp. (NASDAQ:UTHR) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.98 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.59 by $1.39. The company had revenue of $302.20 million for the quarter, compared to the consensus estimate of $279.02 million. During the same quarter in the prior year, the company posted $2.82 earnings per share. The company’s quarterly revenue was up 24.6% on a year-over-year basis. On average, analysts predict that United Therapeutics Corp. will post $5.67 earnings per share for the current fiscal year.

A number of research firms have recently commented on UTHR. Analysts at Argus raised their price target on shares of United Therapeutics Corp. from $120.00 to $130.00 in a research note to investors on Tuesday, December 31st. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Separately, analysts at Jefferies Group raised their price target on shares of United Therapeutics Corp. from $76.00 to $91.00 in a research note to investors on Tuesday, December 24th. They now have a “hold” rating on the stock. Finally, analysts at Ladenburg Thalmann upgraded shares of United Therapeutics Corp. from a “neutral” rating to a “buy” rating in a research note to investors on Monday, December 23rd. They now have a $138.00 price target on the stock. Nine analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $88.21.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.